Sign up to save your podcasts
Or
Share BTK Inhibitors for CLL and MCL: What the Latest Data Mean for Our Patients
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
BTK Inhibitors for CLL and MCL: What the Latest Data Mean for Our Patients
Did you know noncovalent BTK inhibitor therapy is now an option for patients with pretreated MCL who fail a prior covalent BTK inhibitor therapy?
Credit available for this activity expires: 3/21/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/989323?ecd=bdc_podcast_libsyn_mscpedu
View all episodes
By Medscape
4.3
2525 ratings
Did you know noncovalent BTK inhibitor therapy is now an option for patients with pretreated MCL who fail a prior covalent BTK inhibitor therapy?
Credit available for this activity expires: 3/21/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/989323?ecd=bdc_podcast_libsyn_mscpedu
More shows like Keeping Current CME
View all
JAMA Editors' Summary
137 Listeners
AFP: American Family Physician Podcast
697 Listeners
JAMA Clinical Reviews
497 Listeners
JACC This Week
170 Listeners
Diabetes Core Update
105 Listeners
This Week in Cardiology
883 Listeners
The Bob Harrington Show
14 Listeners
One-on-One with Eric Topol
16 Listeners
Mayo Clinic Talks
297 Listeners
Frankly Speaking About Family Medicine
259 Listeners
The Curbsiders Internal Medicine Podcast
3,348 Listeners
Core IM | Internal Medicine Podcast
1,148 Listeners
Annals On Call Podcast
194 Listeners
JAMA Medical News
92 Listeners
The Clinical Problem Solvers
515 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
368 Listeners
Freely Filtered, a NephJC Podcast
171 Listeners
Medicine and the Machine
60 Listeners
Keeping Current
9 Listeners
Cardionerds: A Cardiology Podcast
426 Listeners